---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-056758"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-08-13T20:22:35+00:00"
generated_at: "2026-08-13T20:24:31.772939+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Q2 net loss $33.5M; CMP-002 trial cleared in Australia/Argentina; $50.1M raised

## Summary
- Net loss $33.5M vs $12.6M YoY; includes $20.9M non-cash loss on derivative tranche liability.
- Cash $86.4M at June 30, 2026; plus $50.1M from second closing extends runway to end 2028.
- Regulatory clearance from TGA/HREC (Australia) and ANMAT (Argentina) for Phase 1/2 CMP-002 trial; initiation expected Q4 2026.
- R&D expenses $10.8M vs $10.3M; G&A $4.3M vs $4.2M.
- HQ relocated to Watertown, Mass.; Analyst Day Sept 28, 2026.

## SEC filing metadata
- accession: 0001628280-26-056758
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-08-13T20:22:35+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/0001628280-26-056758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/camp-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-056758
- JSON: https://secwatch.observer/filing/0001628280-26-056758.json
- Plain text: https://secwatch.observer/filing/0001628280-26-056758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.